134 related articles for article (PubMed ID: 26705492)
1. Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses.
Martin JR; Beegle NL; Zhu Y; Hanisch EM
J Adv Pract Oncol; 2015; 6(4):308-18. PubMed ID: 26705492
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous injections: A cross-sectional study of knowledge and practice preferences of nurses.
Fidan Ö; Şanlialp Zeyrek A; Arslan S
Contemp Nurse; 2023 Jun; 59(3):214-226. PubMed ID: 37114438
[TBL] [Abstract][Full Text] [Related]
3. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.
Jin JF; Zhu LL; Chen M; Xu HM; Wang HF; Feng XQ; Zhu XP; Zhou Q
Patient Prefer Adherence; 2015; 9():923-42. PubMed ID: 26170642
[TBL] [Abstract][Full Text] [Related]
4. A systematic review on the factors affecting effective communication between registered nurses and oncology adult patients in an inpatient setting.
Tay LH; Hegney DG; DNurs EA
JBI Libr Syst Rev; 2010; 8(22):869-916. PubMed ID: 27819919
[TBL] [Abstract][Full Text] [Related]
5. Oncology nurses' use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia.
Nirenberg A; Reame NK; Cato KD; Larson EL
Oncol Nurs Forum; 2010 Nov; 37(6):765-73. PubMed ID: 21059588
[TBL] [Abstract][Full Text] [Related]
6. Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site.
Ng P; Incekol D; Lee R; Paisley E; Dara C; Brandle I; Kaufman M; Chen C; Trudel S; Tiedemann R; Reece D; Kukreti V
J Oncol Pharm Pract; 2015 Aug; 21(4):285-92. PubMed ID: 24781451
[TBL] [Abstract][Full Text] [Related]
7. Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18-45 years old.
Gandell DL; Bienen EJ; Gudeman J
Patient Prefer Adherence; 2019; 13():351-361. PubMed ID: 30863023
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.
Barbee MS; Harvey RD; Lonial S; Kaufman JL; Wilson NM; McKibbin T; Hutcherson DA; Surati M; Valla K; Shah KS
Ann Pharmacother; 2013 Sep; 47(9):1136-42. PubMed ID: 24259728
[TBL] [Abstract][Full Text] [Related]
9. In-Hospital Administration of Insulin by Nurses in Northern Greece: An Observational Study.
Theofanidis D
Diabetes Spectr; 2017 Aug; 30(3):175-181. PubMed ID: 28848311
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis.
Ye Z; Chen J; Xuan Z; Yang W; Chen J
Drug Des Devel Ther; 2019; 13():1707-1716. PubMed ID: 31190749
[No Abstract] [Full Text] [Related]
11. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
Upadhyay UD; Zlidar VM; Foster DG
Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
[TBL] [Abstract][Full Text] [Related]
12. Autonomy and empowerment in advanced practice registered nurses: lessons from New Mexico.
Petersen PA; Keller T; Way SM; Borges WJ
J Am Assoc Nurse Pract; 2015 Jul; 27(7):363-70. PubMed ID: 25581473
[TBL] [Abstract][Full Text] [Related]
13. Practical considerations for the integration of subcutaneous targeted therapies into the oncology clinic.
Boudreau A
Can Oncol Nurs J; 2019; 29(4):267-270. PubMed ID: 31966017
[TBL] [Abstract][Full Text] [Related]
14. The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study.
Schutte T; van Eekeren R; Richir M; van Staveren J; van Puijenbroek E; Tichelaar J; van Agtmael M
Naunyn Schmiedebergs Arch Pharmacol; 2018 Jan; 391(1):17-26. PubMed ID: 29063137
[TBL] [Abstract][Full Text] [Related]
15. A systematic review on the relationship between the nursing shortage and nurses' job satisfaction, stress and burnout levels in oncology/haematology settings.
Gi TS; Devi KM; Neo Kim EA
JBI Libr Syst Rev; 2011; 9(39):1603-1649. PubMed ID: 27819963
[TBL] [Abstract][Full Text] [Related]
16. Exploring the work of nurses who administer chemotherapy to children and young people.
Gibson F; Shipway L; Aldiss S; Hawkins J; King W; Parr M; Ridout D; Verity R; Taylor RM
Eur J Oncol Nurs; 2013 Feb; 17(1):59-69. PubMed ID: 22464655
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
18. Central venous access devices: an investigation of oncology nurses' troubleshooting techniques.
Mason TM; Ferrall SM; Boyington AR; Reich RR
Clin J Oncol Nurs; 2014 Aug; 18(4):421-5. PubMed ID: 25095294
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective.
Carlson J; Cox K; Bedwell K; Ku M
Int J Nurs Pract; 2015 Dec; 21 Suppl 3():1-13. PubMed ID: 26681664
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Minarik J; Pavlicek P; Pour L; Pika T; Maisnar V; Spicka I; Jarkovsky J; Krejci M; Bacovsky J; Radocha J; Straub J; Kessler P; Wrobel M; Walterova L; Sykora M; Obernauerova J; Brozova L; Gregora E; Adamova D; Gumulec J; Adam Z; Scudla V; Hajek R;
PLoS One; 2015; 10(4):e0123866. PubMed ID: 25875484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
